Mycobacterium shinjukuense lung disease was diagnosed in 3 men and 3 women [mean age: 77.0±12.2 (57-93) years]. On imaging, 3 patients with previous pulmonary tuberculosis exhibited a fibrocavitary pattern, while the other 3 patients showed nodular bronchiectasis. A test with a tuberculosis rRNA identification kit (TRC Rapid M. TB) was falsely positive for M. tuberculosis due to DNA sequence similarity in 16SrRNA. M. shinjukuense was identified by the gene sequences of rpoB, 16S rRNA, and hsp65. The symptoms and imaging findings of most of the patients have improved with chemotherapy with low minimum inhibitory concentrations of anti-tuberculosis drugs.
Introduction
The number of nontuberculous mycobacteria (NTM) lung diseases, including those caused by rare species, has been increasing in recent years (1, 2) . The NTM distribution differs by country. In Japan, Mycobacterium avium complex (MAC) and M. kansasii account for approximately 83% and 8% of NTM lung disease cases, respectively (3) This study was reviewed and approved by the ethics committee of the National Hospital Organization, Tokyo National Hospital, and was conducted according to the principals expressed in the declaration of Helsinki.
Case Reports
The patients consisted of 3 men and 3 women [mean age: 77.0±12.2 (57-93) years] ( Table 1) . Two representative cases are described below.
Case 1
A 75-year-old man with a history of pulmonary tuberculosis presented to his doctor, who was managing the patient's comorbid diabetes mellitus, with increased sputum, cough, and weight loss. He was referred to our hospital for suspected pulmonary tuberculosis because his sputum smear was positive for acid-fast bacilli. A plain chest X-ray revealed a cavity in the right upper lung field and reduced radiolucency that was predominantly located in the left upper lung field (Fig. 1A) . Chest computed tomography (CT)
Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan, Asthma and Allergy Center, National Hospital Organization Tokyo National Hospital, Japan and The Reference Centre for Mycobacterium, The Research Institute of Tuberculosis, Japan AntiTuberculosis Association, Japan showed a thick-walled cavitary lesion in the right upper lobe, tissue destruction in the left upper lobe, and infiltration on the dorsal side of the left lower lobe (Fig. 1B) . A sputum specimen was identified as positive by a TRC Rapid M. TB assay (Tosoh, Tokyo, Japan) using the transcriptionreverse transcription concerted reaction (TRC) method. The patient was consequently diagnosed with pulmonary tuberculosis and was treated with isoniazid (INH), rifampicin (RFP), ethambutol (EB), and pyrazinamide (PZA). However, because the responsible species was not identified by an MPB64 identification test (Kyapiria TB, TAUNS, Izunokuni, Japan) or a DNA-DNA hybridization mycobacteria "Kyokuto" test (DDH, Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan). On closer examination, M. 
Case 5
A 72-year-old woman with dyslipidemia and angina pectoris was referred to our hospital due to an abnormal chest X-ray, which showed an infiltrative shadow in the bilateral middle and lower lung fields ( Fig. 2A) . Chest CT showed bronchiectasis and an infiltrative shadow in the left lingular segment and the right middle lobe (Fig. 2B) . Her bronchial lavage fluid, which was obtained by bronchoscopy, was found to be positive by a TRC Rapid M. TB assay. Pulmonary tuberculosis was suspected and she was treated with INH, RFP, EB, and PZA. M. shinjukuense was later identified in a culture specimen, resulting in the discontinuation of PZA. The patient is currently under the same treatment and her imaging results have shown improvement (Fig. 2C) .
Five of the 6 patients who were treated in our hospital were given antituberculous drugs following an initial diagnosis of pulmonary tuberculosis due to the false positive reactions of their sputum and bronchoscopy specimens in a TRC Rapid M. TB assay before the identification of M. shinjukuense from culture specimens ( Table 1 ). The symptoms and imaging findings of most patients improved after the administration of combination chemotherapy [INH, RFP, and EB; RFP, EB, and clarithromycin (CAM)]; or erythromycin (EM) monotherapy. With the exception of case 2, the acid-fast bacteria cultures of the patients turned negative within two months. The minimum inhibitory concentrations (MICs) of the various drugs in 5 strains were determined by broth microdilution (brothMIC NTM, Kyokuto Pharmaceutical Industrial Co., Ltd.) ( Table 2 ). The MICs were generally low, particularly for RFP, rifabutin (RBT), and CAM.
Discussion
M. shinjukuense is a slow-growing, non-chromogenic mycobacterium that grows in approximately 21 days at 30-37
. It cannot be identified by DDH but can be identified by rpoB, 16S rRNA, and hsp65 gene sequencing (3) .
Ten cases of M. shinjukuense lung disease (including the present cases) have been reported in Japan (4, 6, 7) . No reports on the disease have been published outside of Japan. When we evaluated the clinical images of 8 cases [mean age: 75.7±11.4 (57-93) years], including the 2 welldocumented cases that were previously reported (Table 1) , 3 patients with previous pulmonary tuberculosis were found to exhibit a fibrocavitary pattern on imaging, whereas the remaining patients had a nodular bronchiectatic pattern.
Caution is required in the diagnosis of M. shinjukuense, because it shows false positive reactions for the TRC Rapid M. TB assay and the DNA probe "FR"-MTD (FUJIREBIO Inc., Tokyo, Japan) (4, 8) . Since the nucleotide sequence of the 16S rRNA gene in M. shinjukuense exhibits high homology to its M. tuberculosis complex counterpart (97.8% homology with the M. tuberculosis ATCC27294 strain), the presence of M. shinjukuense results in false positive reactions on the TRC Rapid M. TB assay. Although the TRC Ready MTB assay targets the 16S rRNA (the same as TRC Rapid M. TB assay), the primer and probe were selected in an area where the RNA sequences of M. shinjukuense and M. tuberculosis differ in order to eliminate false positives. On the re-examination of the 4 strains in cases 1, 2, 4, and 5 with the TRC Ready MTB assay, all of the strains were found to be negative, suggesting that there was no crossreaction. The other genetic tests for the detection of M. tuberculosis [COBAS Taqman MTB (Roche Diagnostics, Tokyo, Japan) and AccuProbe MTB (Hologic, Tokyo, Japan)] yielded negative results (4).
The effective treatments for M. shinjukuense lung disease included combination chemotherapy with RFP, EB, and CAM, as reported by Futatsugi et al. (6) ; and with INH, RFP, and EB, as reported by Watanabe et al. (7) . The administration of both treatments was based on drug susceptibility testing. However, in cases of NTM lung diseases, drug susceptibility results should be carefully handled since the in vitro and in vivo effects could be different (1) . The treatment of lung diseases caused by rare species of NTM, such as M. shinjukuense, should be provided with reference to the existing standards of care for NTM lung disease and the available drug susceptibility results. As shown in Table 2 , there are many low-MIC drugs which have shown high clinical efficacy in the treatment of M. shinjukuense lung disease.
M. shinjukuense lung disease is difficult to differentiate from tuberculosis, especially in patients with previous pulmonary tuberculosis, due to the false positive results that are obtained by certain assays and imaging similarities. A combination chemotherapy, which includes INH, RFP, EB and CAM for one year could be effective in the treatment of M. shinjukuense.
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